IP Library Patent Application 12766259
Patent Application
App. No. 12/766,259

METHODS AND SYSTEMS FOR ADJUSTING THE pH OF MEDICAL BUFFERING SOLUTIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/766,259
Abstract

Buffer solutions within a plurality of containers can be adjusted and controlled by exposing the containers while open to a controlled environment. In particular, an inventory of containers holding bicarbonate buffers can be adjusted to a precisely controlled pH by exposing the containers while open to a controlled carbon dioxide environment in a treatment chamber.

Claims (38)

1 . A method for adjusting pH in a plurality of buffer containers, said method comprising:

positioning each of the containers in a chamber with the container open to expose the buffer to an atmosphere in the chamber;

controlling the pressure, temperature, and CO 2 level of the atmosphere to values selected to provide a target equilibrium pH of the buffer;

holding the containers in the controlled atmosphere of the chamber for a time sufficient for the buffer in each of the containers to reach the target pH; and

sealing each of the containers to inhibit changes in pH over time.

2 . A method as in claim 1 , further comprising moving the containers within the chamber to promote mixing of the atmosphere and mixing of the buffer solution.

3 . A method as in claim 1 , wherein controlling the pressure, temperature, and CO 2 level of the atmosphere comprises introducing, circulating, and removing gas from the chamber.

4 . A method as in claim 3 , wherein the gas is introduced and removed at a substantially constant flow rate.

5 . A method as in claim 4 , wherein the flow rate is in the range from 0.1V to 1V per hour, where V is the open internal volume of the chamber.

6 . A method as in claim 1 , wherein the open containers are held in the chamber for at least 24 hours.

7 . A method as in claim 6 , wherein the open containers are held in the chamber for a time in the range from 24 hours to 96 hours.

8 . A method as in claim 1 , wherein the temperature is in the range from 70° C. to 74° C., the pressure is with 1% of atmospheric, and the CO 2 content is at least 97% by volume, providing a pH in the range from 7.63 to 7.75

9 . A method as in claim 1 , wherein the gas has a 100% relative humidity when introduced to the chamber.

10 . A method as in claim 1 , wherein at least some of the containers include a volume of water which evaporates during the period of time when the container is held in the chamber to raise the relative humidity within the chamber.

11 . A method as in claim 1 , wherein the container is sealed with no headspace remaining after sealing.

12 . A method as in claim 11 , wherein the container is entirely filled while in the chamber.

13 . A method as in claim 11 , wherein the container is partially filled to increase the available open surface area while in the chamber and completely filled prior to sealing.

14 . A method as in claim 13 , wherein the container is completely filled by reducing the volume within the container.

15 . A method as in claim 1 , wherein all containers are identical in shape and volume.

16 . A method as in claim 1 , wherein the containers are sealed while within the chamber.

17 . A method as in claim 1 , wherein the containers are removed from the chamber and then sealed.

18 . A system for adjusting the pH of a plurality of buffer containers, said system comprising:

a chamber having a perimeter wall and an interior;

a gas supply connected to deliver a gas flow into the interior of the chamber, wherein the gas flow comprises at least about 97% by volume carbon dioxide;

a plurality of spaced-apart supports within the interior of the chamber; and

a multiplicity of pneumostatic passages formed through the perimeter wall and located to allow buffer containers to be placed on and removed from each of the supports.

19 . A system as in claim 18 , wherein the chamber comprises a free-standing cabinet.

20 . A system as in claim 18 , wherein a mechanism imparts vibration to the containers, which causes the contents of the container to mix during pH adjustment.

21 . A system as in claim 18 , further comprising a water bath which receives and humidifies the gas flow.

22 . A system as in claim 18 , wherein the supports are present on a rotatable carousel present within the chamber.

23 . A system as in claim 22 , wherein the carousel comprises a plurality of stacked, circular shelves.

24 . An inventory of buffer containers comprising:

a plurality of containers filled with an aqueous solution of a sodium bicarbonate solution, wherein each container in the inventory has:

a volume of sodium bicarbonate solution in the range from 1.0 ml to 50.0 ml; and

a pH variation below ±0.05 when compared to the pH of all other containers in the inventory.

25 . An inventory as in claim 24 , wherein the sodium bicarbonate solution in each container is maintained at a pressure above atmospheric to inhibit the evolution of carbon dioxide during storage.

26 . An inventory as in claim 25 , wherein each container has an open interior filled with the sodium bicarbonate solution, a needle-penetrable septum, a plunger, and a compression member which exerts a force on the plunger which is sufficient to pressurize the sodium bicarbonate solution and inhibit the evolution of carbon dioxide.

27 . An inventory as in claim 24 , further comprising a box which holds the plurality of containers.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Jul 19, 2017
From: ONPHARMA INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0777 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Dec 3, 2014
From: ONPHARMA INC
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 034524/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2010
From: STEPOVICH, MATTHEW J.; FALKEL, MICHAEL I.; NGUYEN, HARRY
To: ONPHARMA, INC.
Reel/Frame 024431/0090 →